BioCentury
ARTICLE | Emerging Company Profile

Relay’s protein motion platform approaches clinical starting line

The $520 million bet on Relay’s platform is slated to get its first clinical test in 2020

January 22, 2020 5:27 PM UTC

With its first program due to enter the clinic this year, Relay will test its hypothesis that characterizing full-length protein targets across a range of conformations leads to better therapeutic candidates than conventional structure-based drug design.

Investors have collectively bet $520 million on Relay Therapeutics Inc.’s approach, which is enabling the company to take multiple cancer programs to the clinic and expand its pipeline beyond oncology (see “Relay Runs Away with $400M Series C”)...

BCIQ Company Profiles

Relay Therapeutics Inc.